leadership
confidence high
sentiment neutral
materiality 0.50
Outlook Therapeutics awards $237,500 retention bonus to CFO/Interim CEO Kenyon
Outlook Therapeutics, Inc.
- Cash retention bonus of $237,500 approved by Compensation Committee on April 9, 2025.
- Bonus payable December 31, 2025, contingent on Kenyon's continuous employment through that date.
- Kenyon declined option to receive stock options in lieu of cash; no election made.
- Upon a qualifying termination before Dec 31, 2025, bonus accelerated subject to release of claims.
- Retention bonus letter filed as Exhibit 10.1 with the 8-K.